Shaping the Future of Liver Research and Toxicology

Fully functional iPSC-derived hepatocyte models (Opti-HEP) for generating pre-clinical human data

Recent News

DefiniGEN / Mon, Jun 3, 2024
DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

Upcoming Events

Gene Therapy Potency Assay Summit 2024
16-18 July 2024 / Boston, MA, United States


Enabling cures for liver disease through highly predictive in vitro modeling

We generate high-quality, phenotypically relevant disease modeled hepatocytes that can be utilized to screen compounds.

Disease Modeling

DefiniGEN's platform technology enables the generation of predictive and phenotypically relevant iPSC-derived human disease models for a wide range of metabolic and liver diseases which can be produced at scale.

Learn more >


Profiling Molecules

Combine our expertise at generating iPSC-derived hepatocyte disease models with our wide panel of bespoke bioassays. We work as partners with your team to design and implement in-house screening of small molecules and advanced genetic therapies, so you can advance your program at speed.

Learn more >


Specialist CRO focused on delivering liver and metabolic disease models

icons_dark blue2
Highly Predictive

Opti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function.

icons_dark blue3


DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocyte-like cells with field leading purity and functionality.

icons_dark blue
Optimized Bioassay Development

Optimized bioassays that can accurately evaluate compound potency, efficacy and delivery.

Scientific expertise

Advance your scientific discoveries with our tailored disease modeling products and services.